T cell and monocyte/macrophage activation markers associate with adverse outcome, but give limited prognostic value in anemic patients with heart failure: results from RED-HF

ConclusionsLeukocyte activation markers sCD163, MIF, sIL-2R, and ALCAM were associated with adverse outcome in patients with HFrEF, but add little as prognostic markers on top of established biochemical risk markers.Clinical Trial Registrationhttps://clinicaltrials.gov/ct2/show/NCT00358215.

http://link.springer.com/10.1007/s00392-018-1331-2

Source: Clinical Research in Cardiology - February 1, 2019 Category: Cardiology Source Type: research